Dermata Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Dermata Therapeutics R&D Spending Growth & History (DRMA)
Dermata Therapeutics's r&d spending was $2.9M for fiscal 2025.
View full Dermata Therapeutics company overviewDermata Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.9M | −$5.3M | −64.28% |
| 2024 | 2024-12-31 | $8.2M | $4.1M | +101.58% |
| 2023 | 2023-12-31 | $4.1M | −$1.6M | −27.98% |
| 2022 | 2022-12-31 | $5.7M | $2.2M | +63.36% |
| 2021 | 2021-12-31 | $3.5M | $1.9M | +115.16% |
| 2020 | 2020-12-31 | $1.6M | — | — |
Dermata Therapeutics quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $212,563 | −$405,272 | −65.60% |
| Q1 2026 | 2026-03-31 | $383,724 | −$897,417 | −70.05% |
| Q4 2025 | 2025-12-31 | $526,620 | −$1.7M | −75.98% |
| Q3 2025 | 2025-09-30 | $504,387 | −$1.9M | −79.00% |
| Q2 2025 | 2025-06-30 | $617,835 | −$1.4M | −69.25% |
| Q1 2025 | 2025-03-31 | $1.3M | −$319,600 | −19.97% |
| Q4 2024 | 2024-12-31 | $2.2M | $1.1M | +93.13% |
| Q3 2024 | 2024-09-30 | $2.4M | $1.5M | +165.94% |
| Q2 2024 | 2024-06-30 | $2.0M | $1.2M | +139.48% |
| Q1 2024 | 2024-03-31 | $1.6M | $408,108 | +34.22% |
| Q4 2023 | 2023-12-31 | $1.1M | $245,870 | +27.65% |
| Q3 2023 | 2023-09-30 | $902,977 | −$650,318 | −41.87% |
| Q2 2023 | 2023-06-30 | $838,931 | −$773,621 | −47.97% |
| Q1 2023 | 2023-03-31 | $1.2M | −$403,206 | −25.27% |
| Q4 2022 | 2022-12-31 | $889,355 | −$222,421 | −20.01% |
| Q3 2022 | 2022-09-30 | $1.6M | $753,516 | +94.22% |
| Q2 2022 | 2022-06-30 | $1.6M | $745,355 | +85.95% |
| Q1 2022 | 2022-03-31 | $1.6M | $915,251 | +134.48% |
| Q4 2021 | 2021-12-31 | $1.1M | — | — |
| Q3 2021 | 2021-09-30 | $799,779 | $679,313 | +563.90% |
| Q2 2021 | 2021-06-30 | $867,197 | $455,248 | +110.51% |
| Q1 2021 | 2021-03-31 | $680,588 | — | — |
| Q3 2020 | 2020-09-30 | $120,466 | — | — |
| Q2 2020 | 2020-06-30 | $411,949 | — | — |
Dermata Therapeutics r&d spending trends
Over the last five fiscal years, Dermata Therapeutics's r&d spending increased from $1.6M to $2.9M, a change of $1.3M. The latest reported quarter, Q2 2026, shows $212,563.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dermata Therapeutics source filings ↗